ERBB2 and breast cancer: Further, a systematic review and meta-analysis studying ErbB2 polymorphism in over 45,000 breast cancer patients showed that there is a lack of experiments replication for association studies between the polymorphic variants and cancer risk, as well as lack of quality control of genotyping assays or publication bias influencing the results (Dahabreh and Murray, 2011).